{"transactions":[{"id":774903,"issuer":{"id":1645,"kind":"organization","name":"Solventum Corp","symbol":"SOLV"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-05-18T17:39:57.000Z","date":"2026-05-15","kind":"grant","planned":false,"acquired":true,"shares":3300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock unit (\"RSU\") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date."}],"balance_after":3300,"derivative":{"underlying":"Common Stock","underlying_shares":3300},"source":{"system":"sec-edgar","filing":"0001474632-26-000008","document":"wk-form4_1779140395.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000147463226000008/wk-form4_1779140395.xml","form_type":"4"}},{"id":795577,"issuer":{"id":1645,"kind":"organization","name":"Solventum Corp","symbol":"SOLV"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-05-01T20:25:44.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":false,"shares":3403,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock unit (\"RSU\") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs are fully vested."}],"balance_after":0,"derivative":{"expiration_date":"2035-04-30","underlying":"Common Stock","underlying_shares":3403},"source":{"system":"sec-edgar","filing":"0001474632-26-000005","document":"wk-form4_1777667141.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000147463226000005/wk-form4_1777667141.xml","form_type":"4"}},{"id":795576,"issuer":{"id":1645,"kind":"organization","name":"Solventum Corp","symbol":"SOLV"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-01T20:25:44.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":true,"shares":3403,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8947,"source":{"system":"sec-edgar","filing":"0001474632-26-000005","document":"wk-form4_1777667141.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000147463226000005/wk-form4_1777667141.xml","form_type":"4"}},{"id":825230,"issuer":{"id":1645,"kind":"organization","name":"Solventum Corp","symbol":"SOLV"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-03-30T23:34:44.000Z","date":"2026-03-27","kind":"exercise","planned":false,"acquired":false,"shares":1980,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock unit (\"RSU\") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs are fully vested."}],"balance_after":0,"derivative":{"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":1980},"source":{"system":"sec-edgar","filing":"0001474632-26-000003","document":"wk-form4_1774913681.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000147463226000003/wk-form4_1774913681.xml","form_type":"4"}},{"id":825229,"issuer":{"id":1645,"kind":"organization","name":"Solventum Corp","symbol":"SOLV"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-30T23:34:44.000Z","date":"2026-03-27","kind":"exercise","planned":false,"acquired":true,"shares":1980,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5544,"source":{"system":"sec-edgar","filing":"0001474632-26-000003","document":"wk-form4_1774913681.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000147463226000003/wk-form4_1774913681.xml","form_type":"4"}},{"id":1095071,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:21:04.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12216,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"(Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"(Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."}],"balance_after":0,"derivative":{"exercise_price":44.77,"underlying":"Common Stock","underlying_shares":12216},"source":{"system":"sec-edgar","filing":"0001104659-25-065303","document":"tm2519678-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000110465925065303/tm2519678-6_4seq1.xml","form_type":"4"}},{"id":1095070,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:21:04.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13774,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"(Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"(Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."}],"balance_after":0,"derivative":{"exercise_price":32.27,"underlying":"Common Stock","underlying_shares":13774},"source":{"system":"sec-edgar","filing":"0001104659-25-065303","document":"tm2519678-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000110465925065303/tm2519678-6_4seq1.xml","form_type":"4"}},{"id":1095069,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:21:04.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30160,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"(Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"(Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."}],"balance_after":0,"derivative":{"exercise_price":28.93,"underlying":"Common Stock","underlying_shares":30160},"source":{"system":"sec-edgar","filing":"0001104659-25-065303","document":"tm2519678-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000110465925065303/tm2519678-6_4seq1.xml","form_type":"4"}},{"id":1095068,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T20:21:04.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28861,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes 13,480 shares underlying restricted stock units (each, an \"RSU\") granted under the Issuer's 2019 Stock Option and Equity Incentive Plan (the \"Plan\"). Each RSU represents a contingent right to receive one share of Issuer common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding RSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such RSU multiplied by (ii) the total number of shares of Issuer common stock subject to such RSU immediately prior to the Effective Time (each a \"Parent Cash-Based RSU Award\"). Each Parent Cash-Based RSU Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such RSU immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based RSU Award will vest, subject to the applicable holder's continued employment with Parent through such date."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-065303","document":"tm2519678-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000110465925065303/tm2519678-6_4seq1.xml","form_type":"4"}},{"id":1147272,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-15T22:42:05.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":10060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The RSUs shall vest in full on the earlier of (i) May 14, 2026 and (ii) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person."}],"balance_after":28861,"source":{"system":"sec-edgar","filing":"0001104659-25-049656","document":"tm2515271-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000110465925049656/tm2515271-2_4seq1.xml","form_type":"4"}},{"id":1147271,"issuer":{"id":1645,"kind":"organization","name":"Solventum Corp","symbol":"SOLV"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-05-15T20:22:25.000Z","date":"2025-05-13","kind":"exercise","planned":false,"acquired":false,"shares":3564,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs fully vested on May 13, 2025."}],"balance_after":0,"derivative":{"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":3564},"source":{"system":"sec-edgar","filing":"0001628280-25-025960","document":"wk-form4_1747340538.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000162828025025960/wk-form4_1747340538.xml","form_type":"4"}},{"id":1147270,"issuer":{"id":1645,"kind":"organization","name":"Solventum Corp","symbol":"SOLV"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-15T20:22:25.000Z","date":"2025-05-13","kind":"exercise","planned":false,"acquired":true,"shares":3564,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3564,"source":{"system":"sec-edgar","filing":"0001628280-25-025960","document":"wk-form4_1747340538.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000162828025025960/wk-form4_1747340538.xml","form_type":"4"}},{"id":1161100,"issuer":{"id":1645,"kind":"organization","name":"Solventum Corp","symbol":"SOLV"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-05-02T20:38:20.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":3403,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs shall fully vest on April 30, 2026, subject to continued service through the vesting date."}],"balance_after":3403,"derivative":{"expiration_date":"2035-04-30","underlying":"Common Stock","underlying_shares":3403},"source":{"system":"sec-edgar","filing":"0001628280-25-021889","document":"wk-form4_1746218276.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000162828025021889/wk-form4_1746218276.xml","form_type":"4"}},{"id":1511239,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-17T20:01:41.000Z","date":"2024-05-16","kind":"grant","planned":false,"acquired":true,"shares":12216,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options shall vest in full on the earlier of (i) May 16, 2025 and (ii) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person."}],"balance_after":12216,"derivative":{"exercise_price":44.77,"expiration_date":"2034-05-16","underlying":"Common Stock","underlying_shares":12216},"source":{"system":"sec-edgar","filing":"0001104659-24-062975","document":"tm2414847-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000110465924062975/tm2414847-1_4seq1.xml","form_type":"4"}},{"id":1511238,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-17T20:01:41.000Z","date":"2024-05-16","kind":"grant","planned":false,"acquired":true,"shares":4095,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The RSUs shall vest in full on the earlier of (i) May 16, 2025 and (ii) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person."}],"balance_after":18801,"source":{"system":"sec-edgar","filing":"0001104659-24-062975","document":"tm2414847-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000110465924062975/tm2414847-1_4seq1.xml","form_type":"4"}},{"id":1515898,"issuer":{"id":1645,"kind":"organization","name":"Solventum Corp","symbol":"SOLV"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2024-05-15T20:54:35.000Z","date":"2024-05-13","kind":"grant","planned":false,"acquired":true,"shares":1980,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock unit (\"RSU\") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs shall fully vest on March 27, 2026, subject to continued service through the vesting date."}],"balance_after":5544,"derivative":{"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":1980},"source":{"system":"sec-edgar","filing":"0001127602-24-015492","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000112760224015492/form4.xml","form_type":"4"}},{"id":1515897,"issuer":{"id":1645,"kind":"organization","name":"Solventum Corp","symbol":"SOLV"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2024-05-15T20:54:35.000Z","date":"2024-05-13","kind":"grant","planned":false,"acquired":true,"shares":3564,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock unit (\"RSU\") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs shall fully vest on May 13, 2025, subject to continued service through the vesting date."}],"balance_after":3564,"derivative":{"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":3564},"source":{"system":"sec-edgar","filing":"0001127602-24-015492","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000112760224015492/form4.xml","form_type":"4"}},{"id":1878018,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-25T20:24:35.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":13774,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options shall vest in full on the earlier of (1) May 24, 2024 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person."}],"balance_after":13774,"derivative":{"exercise_price":32.27,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":13774},"source":{"system":"sec-edgar","filing":"0001104659-23-064644","document":"tm2317015-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000110465923064644/tm2317015-1_4seq1.xml","form_type":"4"}},{"id":1878017,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-25T20:24:35.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":4648,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The RSUs shall vest in full on the earlier of (1) May 24, 2024 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person."}],"balance_after":14706,"source":{"system":"sec-edgar","filing":"0001104659-23-064644","document":"tm2317015-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000110465923064644/tm2317015-1_4seq1.xml","form_type":"4"}},{"id":2206966,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-15T10:07:12.000Z","date":"2022-07-14","kind":"grant","acquired":true,"shares":30160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for initial equity grants to the Issuer's non-employee directors on the date of the Reporting Person's commencement of service to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options shall vest in equal monthly installments over 36 months following July 14, 2022, subject to continued service to the Issuer by the Reporting Person."}],"balance_after":30160,"derivative":{"exercise_price":28.93,"expiration_date":"2032-07-14","underlying":"Common Stock","underlying_shares":30160},"source":{"system":"sec-edgar","filing":"0001104659-22-079983","document":"tm2221127-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000110465922079983/tm2221127-3_4seq1.xml","form_type":"4"}},{"id":2206965,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-15T10:07:12.000Z","date":"2022-07-14","kind":"grant","acquired":true,"shares":10058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for initial equity grants to the Issuer's non-employee directors on the date of the Reporting Person's commencement of service to the Issuer. The RSUs shall vest in three (3) equal annual installments following July 14, 2022, subject to continued service to the Issuer by the Reporting Person."}],"balance_after":10058,"source":{"system":"sec-edgar","filing":"0001104659-22-079983","document":"tm2221127-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000110465922079983/tm2221127-3_4seq1.xml","form_type":"4"}},{"id":98321,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Option(Right to buy)","published_at":"2020-11-18T22:04:53.000Z","date":"2020-11-16","kind":"exercise","acquired":false,"shares":115830,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3."}],"balance_after":0,"derivative":{"exercise_price":35.88,"exercise_date":"2014-02-14","expiration_date":"2023-02-13","underlying":"Common Stock","underlying_shares":115830},"source":{"system":"sec-edgar","filing":"0001179110-20-011204","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911020011204/edgar.xml","form_type":"4"}},{"id":98320,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-11-18T22:04:53.000Z","date":"2020-11-16","kind":"sale","acquired":false,"shares":115830,"price":100,"value":11583000.0,"ownership":{"direct":true},"balance_after":114899,"source":{"system":"sec-edgar","filing":"0001179110-20-011204","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911020011204/edgar.xml","form_type":"4"}},{"id":98319,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-11-18T22:04:53.000Z","date":"2020-11-16","kind":"exercise","acquired":true,"shares":115830,"price":35.88,"value":4155980.4,"ownership":{"direct":true},"balance_after":230729,"source":{"system":"sec-edgar","filing":"0001179110-20-011204","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911020011204/edgar.xml","form_type":"4"}},{"id":103360,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-07-09T01:19:47.000Z","date":"2020-07-07","kind":"sale","acquired":false,"shares":23000,"price":100,"value":2300000.0,"ownership":{"direct":true},"balance_after":114899,"source":{"system":"sec-edgar","filing":"0001179110-20-008118","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911020008118/edgar.xml","form_type":"4"}},{"id":103359,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-07-09T01:19:47.000Z","date":"2020-07-07","kind":"sale","acquired":false,"shares":30325,"price":100.0018,"value":3032554.585,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.03, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":137899,"source":{"system":"sec-edgar","filing":"0001179110-20-008118","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911020008118/edgar.xml","form_type":"4"}},{"id":106578,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-03-03T21:51:00.000Z","date":"2020-02-28","kind":"tax_withholding","acquired":false,"shares":32092,"price":85.42,"value":2741298.64,"ownership":{"direct":true},"balance_after":168224,"source":{"system":"sec-edgar","filing":"0001179110-20-002851","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911020002851/edgar.xml","form_type":"4"}},{"id":107138,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Option (right to buy)","published_at":"2020-02-24T23:04:50.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":114566,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F6","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,189 on February 20, 2021, 38,189 on February 20, 2022, and 38,188 on February 20, 2023."}],"balance_after":114566,"derivative":{"exercise_price":93.5,"exercise_date":"2021-02-20","expiration_date":"2030-02-19","underlying":"Common Stock","underlying_shares":114566},"source":{"system":"sec-edgar","filing":"0001179110-20-002137","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911020002137/edgar.xml","form_type":"4"}},{"id":107137,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-02-24T23:04:50.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":10125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020."}],"balance_after":200316,"source":{"system":"sec-edgar","filing":"0001179110-20-002137","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911020002137/edgar.xml","form_type":"4"}},{"id":107136,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-02-24T23:04:50.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":8214,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020."}],"balance_after":190191,"source":{"system":"sec-edgar","filing":"0001179110-20-002137","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911020002137/edgar.xml","form_type":"4"}},{"id":107135,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-02-24T23:04:50.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":14340,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020."}],"balance_after":181977,"source":{"system":"sec-edgar","filing":"0001179110-20-002137","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911020002137/edgar.xml","form_type":"4"}},{"id":107134,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-02-24T23:04:50.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":39760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020."}],"balance_after":167637,"source":{"system":"sec-edgar","filing":"0001179110-20-002137","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911020002137/edgar.xml","form_type":"4"}},{"id":118974,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Common Stock, $0.01 par value","published_at":"2019-03-04T21:53:30.000Z","date":"2019-02-28","kind":"tax_withholding","acquired":false,"shares":24125,"price":79.41,"value":1915766.25,"ownership":{"direct":true},"balance_after":127877,"source":{"system":"sec-edgar","filing":"0001179110-19-003072","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911019003072/edgar.xml","form_type":"4"}},{"id":119480,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Option (right to buy)","published_at":"2019-02-22T22:20:04.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":62305,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F6","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,769 on February 21, 2020, 20,768 on February 21, 2021, and 20,768 on February 21, 2022."}],"balance_after":62305,"derivative":{"exercise_price":79.02,"exercise_date":"2020-02-21","expiration_date":"2029-02-20","underlying":"Common Stock","underlying_shares":62305},"source":{"system":"sec-edgar","filing":"0001179110-19-002369","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911019002369/edgar.xml","form_type":"4"}},{"id":119479,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Common stock, $0.01 par value","published_at":"2019-02-22T22:20:04.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":8215,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019."}],"balance_after":152002,"source":{"system":"sec-edgar","filing":"0001179110-19-002369","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911019002369/edgar.xml","form_type":"4"}},{"id":119478,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Common stock, $0.01 par value","published_at":"2019-02-22T22:20:04.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":14340,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019."}],"balance_after":143787,"source":{"system":"sec-edgar","filing":"0001179110-19-002369","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911019002369/edgar.xml","form_type":"4"}},{"id":119477,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Common stock, $0.01 par value","published_at":"2019-02-22T22:20:04.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":13350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019."}],"balance_after":129447,"source":{"system":"sec-edgar","filing":"0001179110-19-002369","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911019002369/edgar.xml","form_type":"4"}},{"id":119476,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice Chairman"}}],"security":"Common stock, $0.01 par value","published_at":"2019-02-22T22:20:04.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":18545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019."}],"balance_after":116097,"source":{"system":"sec-edgar","filing":"0001179110-19-002369","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911019002369/edgar.xml","form_type":"4"}},{"id":131354,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Option (right to buy)","published_at":"2018-03-02T22:29:25.000Z","date":"2018-03-01","kind":"exercise","acquired":false,"shares":48100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F6","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3."}],"balance_after":0,"derivative":{"exercise_price":29.2265,"exercise_date":"2015-02-17","expiration_date":"2022-02-16","underlying":"Common Stock","underlying_shares":48100},"source":{"system":"sec-edgar","filing":"0001179110-18-003335","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911018003335/edgar.xml","form_type":"4"}},{"id":131353,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2018-03-02T22:29:25.000Z","date":"2018-03-01","kind":"sale","acquired":false,"shares":14829,"price":114.4278,"value":1696849.8462,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.00 to $115.965, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":97552,"source":{"system":"sec-edgar","filing":"0001179110-18-003335","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911018003335/edgar.xml","form_type":"4"}},{"id":131352,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2018-03-02T22:29:25.000Z","date":"2018-03-01","kind":"sale","acquired":false,"shares":46997,"price":114.6342,"value":5387463.4974,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.00 to $114.965, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":112381,"source":{"system":"sec-edgar","filing":"0001179110-18-003335","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911018003335/edgar.xml","form_type":"4"}},{"id":131351,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2018-03-02T22:29:25.000Z","date":"2018-03-01","kind":"sale","acquired":false,"shares":19169,"price":113.7511,"value":2180494.8359,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.53 to $113.97, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":159378,"source":{"system":"sec-edgar","filing":"0001179110-18-003335","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911018003335/edgar.xml","form_type":"4"}},{"id":131350,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2018-03-02T22:29:25.000Z","date":"2018-03-01","kind":"exercise","acquired":true,"shares":48100,"price":29.2265,"value":1405794.65,"ownership":{"direct":true},"balance_after":178547,"source":{"system":"sec-edgar","filing":"0001179110-18-003335","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911018003335/edgar.xml","form_type":"4"}},{"id":131349,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2018-03-02T22:29:25.000Z","date":"2018-02-28","kind":"sale","acquired":false,"shares":2579,"price":117.8474,"value":303928.4446,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.847 to $117.861, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":130447,"source":{"system":"sec-edgar","filing":"0001179110-18-003335","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911018003335/edgar.xml","form_type":"4"}},{"id":131348,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2018-03-02T22:29:25.000Z","date":"2018-02-28","kind":"tax_withholding","acquired":false,"shares":25976,"price":118.26,"value":3071921.76,"ownership":{"direct":true},"balance_after":133026,"source":{"system":"sec-edgar","filing":"0001179110-18-003335","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911018003335/edgar.xml","form_type":"4"}},{"id":132322,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Option (right to buy)","published_at":"2018-02-16T22:53:13.000Z","date":"2018-02-15","kind":"grant","acquired":true,"shares":44430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 14,810 on February 15, 2019, 14,810 on February 15, 2020, and 14,810 on February 15, 2021."}],"balance_after":44430,"derivative":{"exercise_price":114.36,"exercise_date":"2019-02-15","expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":44430},"source":{"system":"sec-edgar","filing":"0001179110-18-002297","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911018002297/edgar.xml","form_type":"4"}},{"id":132321,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2018-02-16T22:53:13.000Z","date":"2018-02-15","kind":"grant","acquired":true,"shares":14340,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018."}],"balance_after":159002,"source":{"system":"sec-edgar","filing":"0001179110-18-002297","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911018002297/edgar.xml","form_type":"4"}},{"id":132320,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2018-02-16T22:53:13.000Z","date":"2018-02-15","kind":"grant","acquired":true,"shares":16567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018."}],"balance_after":144662,"source":{"system":"sec-edgar","filing":"0001179110-18-002297","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911018002297/edgar.xml","form_type":"4"}},{"id":132319,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2018-02-16T22:53:13.000Z","date":"2018-02-15","kind":"grant","acquired":true,"shares":13350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018."}],"balance_after":128950,"source":{"system":"sec-edgar","filing":"0001179110-18-002297","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911018002297/edgar.xml","form_type":"4"}},{"id":139570,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Option (right to buy)","published_at":"2017-06-15T21:05:08.000Z","date":"2017-06-14","kind":"exercise","acquired":false,"shares":45800,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":24.2082,"exercise_date":"2014-02-18","expiration_date":"2021-02-17","underlying":"Common stock","underlying_shares":45800},"source":{"system":"sec-edgar","filing":"0001179110-17-009114","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911017009114/edgar.xml","form_type":"4"}},{"id":139569,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2017-06-15T21:05:08.000Z","date":"2017-06-14","kind":"sale","acquired":false,"shares":45800,"price":70,"value":3206000.0,"ownership":{"direct":true},"balance_after":114745,"source":{"system":"sec-edgar","filing":"0001179110-17-009114","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911017009114/edgar.xml","form_type":"4"}},{"id":139568,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2017-06-15T21:05:08.000Z","date":"2017-06-14","kind":"exercise","acquired":true,"shares":45800,"price":24.2082,"value":1108735.56,"ownership":{"direct":true},"balance_after":160545,"source":{"system":"sec-edgar","filing":"0001179110-17-009114","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911017009114/edgar.xml","form_type":"4"}},{"id":140843,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2017-05-08T21:13:13.000Z","date":"2017-05-04","kind":"sale","acquired":false,"shares":43000,"price":67,"value":2881000.0,"ownership":{"direct":true},"balance_after":114745,"source":{"system":"sec-edgar","filing":"0001179110-17-006837","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911017006837/edgar.xml","form_type":"4"}},{"id":142499,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2017-03-02T23:10:45.000Z","date":"2017-02-28","kind":"tax_withholding","acquired":false,"shares":34721,"price":62.22,"value":2160340.62,"ownership":{"direct":true},"balance_after":157745,"source":{"system":"sec-edgar","filing":"0001179110-17-003699","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911017003699/edgar.xml","form_type":"4"}},{"id":143043,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Option (right to buy)","published_at":"2017-02-21T22:50:07.000Z","date":"2017-02-16","kind":"grant","acquired":true,"shares":95750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 31,917 on 02/16/2018, 31,916 on 02/16/2019, and 31,917 on 02/16/2020."}],"balance_after":95750,"derivative":{"exercise_price":61.36,"exercise_date":"2018-02-16","expiration_date":"2027-02-15","underlying":"Common stock","underlying_shares":95750},"source":{"system":"sec-edgar","filing":"0001179110-17-002804","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911017002804/edgar.xml","form_type":"4"}},{"id":143042,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2017-02-21T22:50:07.000Z","date":"2017-02-16","kind":"grant","acquired":true,"shares":13350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017."}],"balance_after":192466,"source":{"system":"sec-edgar","filing":"0001179110-17-002804","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911017002804/edgar.xml","form_type":"4"}},{"id":143041,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2017-02-21T22:50:07.000Z","date":"2017-02-16","kind":"grant","acquired":true,"shares":29672,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017."}],"balance_after":179116,"source":{"system":"sec-edgar","filing":"0001179110-17-002804","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911017002804/edgar.xml","form_type":"4"}},{"id":152899,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2016-05-12T21:39:55.000Z","date":"2016-05-10","kind":"sale","acquired":false,"shares":47438,"price":63.52,"value":3013261.76,"ownership":{"direct":true},"balance_after":149444,"source":{"system":"sec-edgar","filing":"0001179110-16-024454","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911016024454/edgar.xml","form_type":"4"}},{"id":155267,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2016-03-02T22:18:49.000Z","date":"2016-02-29","kind":"tax_withholding","acquired":false,"shares":39930,"price":56,"value":2236080.0,"ownership":{"direct":true},"balance_after":196882,"source":{"system":"sec-edgar","filing":"0001179110-16-020675","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911016020675/edgar.xml","form_type":"4"}},{"id":155727,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Option (right to buy)","published_at":"2016-02-22T22:05:32.000Z","date":"2016-02-18","kind":"grant","acquired":true,"shares":79870,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exerciseable in annual increments of 26,624 on 02/18/2017, 26,623 on 02/18/2018, and 26,623 on 02/18/2019."}],"balance_after":79870,"derivative":{"exercise_price":54.86,"exercise_date":"2017-02-18","expiration_date":"2026-02-17","underlying":"Common stock","underlying_shares":79870},"source":{"system":"sec-edgar","filing":"0001179110-16-019777","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911016019777/edgar.xml","form_type":"4"}},{"id":166100,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2015-03-03T23:03:43.000Z","date":"2015-02-28","kind":"tax_withholding","acquired":false,"shares":7200,"price":60.5,"value":435600.0,"ownership":{"direct":true},"balance_after":236812,"source":{"system":"sec-edgar","filing":"0001179110-15-004093","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911015004093/edgar.xml","form_type":"4"}},{"id":166099,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2015-03-03T23:03:43.000Z","date":"2015-02-27","kind":"tax_withholding","acquired":false,"shares":12706,"price":60.52,"value":768967.12,"ownership":{"direct":true},"balance_after":244012,"source":{"system":"sec-edgar","filing":"0001179110-15-004093","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911015004093/edgar.xml","form_type":"4"}},{"id":166354,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Option (right to buy)","published_at":"2015-02-23T22:07:07.000Z","date":"2015-02-19","kind":"grant","acquired":true,"shares":101960,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exerciseable in annual increments of 33,987 on 02/19/2016, 33,986 on 02/19/2017, and 33,987 on 02/19/2018."}],"balance_after":101960,"derivative":{"exercise_price":58.88,"exercise_date":"2016-02-19","expiration_date":"2025-02-18","underlying":"Common stock","underlying_shares":101960},"source":{"system":"sec-edgar","filing":"0001179110-15-003160","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911015003160/edgar.xml","form_type":"4"}},{"id":166353,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2015-02-23T22:07:07.000Z","date":"2015-02-19","kind":"grant","acquired":true,"shares":51580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities represent performance vested restricted stock awards under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes."}],"balance_after":256718,"source":{"system":"sec-edgar","filing":"0001179110-15-003160","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911015003160/edgar.xml","form_type":"4"}},{"id":175702,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2014-03-04T22:10:48.000Z","date":"2014-03-03","kind":"sale","acquired":false,"shares":600,"price":50.094,"value":30056.4,"ownership":{"direct":true},"balance_after":205138,"source":{"system":"sec-edgar","filing":"0001179110-14-004322","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911014004322/edgar.xml","form_type":"4"}},{"id":175701,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2014-03-04T22:10:48.000Z","date":"2014-03-03","kind":"sale","acquired":false,"shares":400,"price":50.091,"value":20036.4,"ownership":{"direct":true},"balance_after":205738,"source":{"system":"sec-edgar","filing":"0001179110-14-004322","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911014004322/edgar.xml","form_type":"4"}},{"id":175700,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2014-03-04T22:10:48.000Z","date":"2014-03-03","kind":"sale","acquired":false,"shares":282,"price":50.09,"value":14125.38,"ownership":{"direct":true},"balance_after":206138,"source":{"system":"sec-edgar","filing":"0001179110-14-004322","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911014004322/edgar.xml","form_type":"4"}},{"id":175699,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2014-03-04T22:10:48.000Z","date":"2014-03-03","kind":"sale","acquired":false,"shares":1600,"price":50.086,"value":80137.6,"ownership":{"direct":true},"balance_after":206420,"source":{"system":"sec-edgar","filing":"0001179110-14-004322","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911014004322/edgar.xml","form_type":"4"}},{"id":175698,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2014-03-04T22:10:48.000Z","date":"2014-02-28","kind":"tax_withholding","acquired":false,"shares":15319,"price":50.91,"value":779890.29,"ownership":{"direct":true},"balance_after":208020,"source":{"system":"sec-edgar","filing":"0001179110-14-004322","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911014004322/edgar.xml","form_type":"4"}},{"id":176033,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Option (right to buy)","published_at":"2014-02-24T22:06:08.000Z","date":"2014-02-20","kind":"grant","acquired":true,"shares":81500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exerciseable in annual increments of 27,167 on 02/20/2015, 27,166 on 02/20/2016, and 27,167 on 02/20/2017."}],"balance_after":81500,"derivative":{"exercise_price":51.42,"exercise_date":"2015-02-20","expiration_date":"2024-02-19","underlying":"Common stock","underlying_shares":81500},"source":{"system":"sec-edgar","filing":"0001179110-14-003466","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911014003466/edgar.xml","form_type":"4"}},{"id":176032,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2014-02-24T22:06:08.000Z","date":"2014-02-20","kind":"grant","acquired":true,"shares":47260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities represent performance vested restricted stock awards under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes."}],"balance_after":223339,"source":{"system":"sec-edgar","filing":"0001179110-14-003466","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911014003466/edgar.xml","form_type":"4"}},{"id":184648,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Option (right to buy)","published_at":"2013-05-03T21:27:53.000Z","date":"2013-05-01","kind":"exercise","acquired":false,"shares":34600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3."}],"balance_after":0,"derivative":{"exercise_price":28.3122,"exercise_date":"2013-02-19","expiration_date":"2020-02-18","underlying":"Common stock","underlying_shares":34600},"source":{"system":"sec-edgar","filing":"0001179110-13-007704","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911013007704/edgar.xml","form_type":"4"}},{"id":184647,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Option (right to buy)","published_at":"2013-05-03T21:27:53.000Z","date":"2013-05-01","kind":"exercise","acquired":false,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3."}],"balance_after":0,"derivative":{"exercise_price":26.8472,"exercise_date":"2012-10-15","expiration_date":"2019-10-14","underlying":"Common stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001179110-13-007704","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911013007704/edgar.xml","form_type":"4"}},{"id":184646,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Option (right to buy)","published_at":"2013-05-03T21:27:53.000Z","date":"2013-05-01","kind":"exercise","acquired":false,"shares":17700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3."}],"balance_after":0,"derivative":{"exercise_price":28.1251,"exercise_date":"2012-02-20","expiration_date":"2019-02-19","underlying":"Common stock","underlying_shares":17700},"source":{"system":"sec-edgar","filing":"0001179110-13-007704","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911013007704/edgar.xml","form_type":"4"}},{"id":184645,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Option (right to buy)","published_at":"2013-05-03T21:27:53.000Z","date":"2013-05-01","kind":"exercise","acquired":false,"shares":33900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3."}],"balance_after":0,"derivative":{"exercise_price":28.8628,"exercise_date":"2011-02-15","expiration_date":"2018-02-14","underlying":"Common stock","underlying_shares":33900},"source":{"system":"sec-edgar","filing":"0001179110-13-007704","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911013007704/edgar.xml","form_type":"4"}},{"id":184644,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Option (right to buy)","published_at":"2013-05-03T21:27:53.000Z","date":"2013-05-01","kind":"exercise","acquired":false,"shares":35700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3."}],"balance_after":0,"derivative":{"exercise_price":27.294,"exercise_date":"2010-02-16","expiration_date":"2017-02-15","underlying":"Common stock","underlying_shares":35700},"source":{"system":"sec-edgar","filing":"0001179110-13-007704","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911013007704/edgar.xml","form_type":"4"}},{"id":184643,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2013-05-03T21:27:53.000Z","date":"2013-05-01","kind":"sale","acquired":false,"shares":27664,"price":45.6797,"value":1263683.2208,"ownership":{"direct":true},"balance_after":176079,"source":{"system":"sec-edgar","filing":"0001179110-13-007704","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911013007704/edgar.xml","form_type":"4"}},{"id":184642,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2013-05-03T21:27:53.000Z","date":"2013-05-01","kind":"sale","acquired":false,"shares":30550,"price":45.6768,"value":1395426.24,"ownership":{"direct":true},"balance_after":203743,"source":{"system":"sec-edgar","filing":"0001179110-13-007704","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911013007704/edgar.xml","form_type":"4"}},{"id":184641,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2013-05-03T21:27:53.000Z","date":"2013-05-01","kind":"sale","acquired":false,"shares":27320,"price":45.6648,"value":1247562.336,"ownership":{"direct":true},"balance_after":234293,"source":{"system":"sec-edgar","filing":"0001179110-13-007704","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911013007704/edgar.xml","form_type":"4"}},{"id":184640,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2013-05-03T21:27:53.000Z","date":"2013-05-01","kind":"sale","acquired":false,"shares":28122,"price":45.6837,"value":1284717.0114,"ownership":{"direct":true},"balance_after":261613,"source":{"system":"sec-edgar","filing":"0001179110-13-007704","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911013007704/edgar.xml","form_type":"4"}},{"id":184639,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2013-05-03T21:27:53.000Z","date":"2013-05-01","kind":"exercise","acquired":true,"shares":34600,"price":28.3122,"value":979602.12,"ownership":{"direct":true},"balance_after":289735,"source":{"system":"sec-edgar","filing":"0001179110-13-007704","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911013007704/edgar.xml","form_type":"4"}},{"id":184638,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2013-05-03T21:27:53.000Z","date":"2013-05-01","kind":"exercise","acquired":true,"shares":21000,"price":26.8472,"value":563791.2,"ownership":{"direct":true},"balance_after":255135,"source":{"system":"sec-edgar","filing":"0001179110-13-007704","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911013007704/edgar.xml","form_type":"4"}},{"id":184637,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2013-05-03T21:27:53.000Z","date":"2013-05-01","kind":"exercise","acquired":true,"shares":17700,"price":28.1251,"value":497814.27,"ownership":{"direct":true},"balance_after":234135,"source":{"system":"sec-edgar","filing":"0001179110-13-007704","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911013007704/edgar.xml","form_type":"4"}},{"id":184636,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2013-05-03T21:27:53.000Z","date":"2013-05-01","kind":"exercise","acquired":true,"shares":33900,"price":28.8628,"value":978448.92,"ownership":{"direct":true},"balance_after":216435,"source":{"system":"sec-edgar","filing":"0001179110-13-007704","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911013007704/edgar.xml","form_type":"4"}},{"id":184635,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2013-05-03T21:27:53.000Z","date":"2013-05-01","kind":"exercise","acquired":true,"shares":35700,"price":27.294,"value":974395.8,"ownership":{"direct":true},"balance_after":182535,"source":{"system":"sec-edgar","filing":"0001179110-13-007704","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911013007704/edgar.xml","form_type":"4"}},{"id":186442,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2013-03-04T22:09:42.000Z","date":"2013-02-28","kind":"tax_withholding","acquired":false,"shares":12960,"price":36.73,"value":476020.8,"ownership":{"direct":true},"balance_after":146835,"source":{"system":"sec-edgar","filing":"0001179110-13-004015","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911013004015/edgar.xml","form_type":"4"}},{"id":186889,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Option (right to buy)","published_at":"2013-02-20T00:06:51.000Z","date":"2013-02-14","kind":"grant","acquired":true,"shares":115830,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exerciseable in annual increments of 38,610 on 02/14/2014, 38,610 on 02/14/2015, and 38,610 on 02/14/2016."}],"balance_after":115830,"derivative":{"exercise_price":35.88,"exercise_date":"2014-02-14","expiration_date":"2023-02-13","underlying":"Common stock","underlying_shares":115830},"source":{"system":"sec-edgar","filing":"0001179110-13-003031","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911013003031/edgar.xml","form_type":"4"}},{"id":186888,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2013-02-20T00:06:51.000Z","date":"2013-02-19","kind":"tax_withholding","acquired":false,"shares":9826,"price":37.58,"value":369261.08,"ownership":{"direct":true},"balance_after":159795,"source":{"system":"sec-edgar","filing":"0001179110-13-003031","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911013003031/edgar.xml","form_type":"4"}},{"id":186887,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2013-02-20T00:06:51.000Z","date":"2013-02-14","kind":"grant","acquired":true,"shares":56700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities represent performance vested restricted stock awards under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes."}],"balance_after":169621,"source":{"system":"sec-edgar","filing":"0001179110-13-003031","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911013003031/edgar.xml","form_type":"4"}},{"id":187259,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Option (right to buy)","published_at":"2013-02-07T21:44:22.000Z","date":"2013-02-05","kind":"exercise","acquired":false,"shares":2482,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":33.798,"exercise_date":"2013-01-24","expiration_date":"2013-02-13","underlying":"Common stock","underlying_shares":2482},"source":{"system":"sec-edgar","filing":"0001179110-13-002137","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911013002137/edgar.xml","form_type":"4"}},{"id":187258,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2013-02-07T21:44:22.000Z","date":"2013-02-05","kind":"tax_withholding","acquired":false,"shares":2325,"price":37.28,"value":86676.0,"ownership":{"direct":true},"balance_after":112921,"source":{"system":"sec-edgar","filing":"0001179110-13-002137","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911013002137/edgar.xml","form_type":"4"}},{"id":187257,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Operations"}}],"security":"Common stock, $0.01 par value","published_at":"2013-02-07T21:44:22.000Z","date":"2013-02-05","kind":"exercise","acquired":true,"shares":2482,"price":33.798,"value":83886.636,"ownership":{"direct":true},"balance_after":115246,"source":{"system":"sec-edgar","filing":"0001179110-13-002137","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1474632/000117911013002137/edgar.xml","form_type":"4"}},{"id":485370,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2012-12-04T22:11:38.000Z","date":"2012-11-16","kind":"gift","acquired":true,"shares":40442,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Maria Cristina Alban 2007 Declaration of Trust"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Held in the Maria Cristina Alban 2007 Declaration of Trust. The reporting person's spouse is trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities."}],"balance_after":40442,"source":{"system":"sec-edgar","filing":"0001179110-12-016883","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911012016883/edgar.xml","form_type":"4"}},{"id":485369,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2012-12-04T22:11:38.000Z","date":"2012-12-01","kind":"grant","acquired":true,"shares":18453,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards will cliff vest after January 1, 2016, subject to AbbVie reaching a minimum average return on equity target for the period 2013 through 2015. The awards include the right to have stock withheld for tax purposes."}],"balance_after":95696,"source":{"system":"sec-edgar","filing":"0001179110-12-016883","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911012016883/edgar.xml","form_type":"4"}},{"id":485368,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2012-12-04T22:11:38.000Z","date":"2012-11-16","kind":"gift","acquired":false,"shares":40442,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":77243,"source":{"system":"sec-edgar","filing":"0001179110-12-016883","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911012016883/edgar.xml","form_type":"4"}},{"id":487157,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2012-10-17T21:03:26.000Z","date":"2012-10-15","kind":"tax_withholding","acquired":false,"shares":2032,"price":69.28,"value":140776.96,"ownership":{"direct":true},"balance_after":117685,"source":{"system":"sec-edgar","filing":"0001179110-12-015251","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911012015251/edgar.xml","form_type":"4"}},{"id":487156,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2012-10-17T21:03:26.000Z","date":"2012-10-15","kind":"grant","acquired":true,"shares":4900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3."}],"balance_after":119717,"source":{"system":"sec-edgar","filing":"0001179110-12-015251","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911012015251/edgar.xml","form_type":"4"}},{"id":487642,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Option (right to buy)","published_at":"2012-09-27T21:10:29.000Z","date":"2012-09-25","kind":"exercise","acquired":false,"shares":1198,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3."}],"balance_after":0,"derivative":{"exercise_price":57.25,"exercise_date":"2009-03-19","expiration_date":"2014-02-19","underlying":"Common shares","underlying_shares":1198},"source":{"system":"sec-edgar","filing":"0001179110-12-014554","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911012014554/edgar.xml","form_type":"4"}},{"id":487641,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2012-09-27T21:10:29.000Z","date":"2012-09-25","kind":"sale","acquired":false,"shares":1198,"price":70,"value":83860.0,"ownership":{"direct":true},"balance_after":114817,"source":{"system":"sec-edgar","filing":"0001179110-12-014554","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911012014554/edgar.xml","form_type":"4"}},{"id":487640,"issuer":{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT"},"owners":[{"id":11830,"kind":"person","name":"ALBAN CARLOS","position":1,"cik":"0001474632","reported_name":"ALBAN CARLOS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common shares without par value","published_at":"2012-09-27T21:10:29.000Z","date":"2012-09-25","kind":"exercise","acquired":true,"shares":1198,"price":57.25,"value":68585.5,"ownership":{"direct":true},"balance_after":116015,"source":{"system":"sec-edgar","filing":"0001179110-12-014554","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911012014554/edgar.xml","form_type":"4"}}],"next_cursor":"2012-09-27T21:10:29.000000Z,487640"}